Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Why Shares of ProQR Therapeutics Dropped on Wednesday
The clinical-stage biotech released fourth-quarter and full-year earnings. 
Via The Motley Fool
Nasdaq Rises 1%; US Pending Home Sales Increase In February
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.58% to 32,580.89 while the NASDAQ rose 1.09% to 11,843.85. The S&P... 
Via Benzinga
US Stocks Open Higher, Dow Jumps Over 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33%... 
Via Benzinga
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
From ProQR Therapeutics N.V.
Via GlobeNewswire
Earnings Outlook For ProQR Therapeutics
 
Via Benzinga
Raymond James Bullish On This Penny Stock's Reprioritized Pipeline
 
Via Benzinga
This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing
 
Via Benzinga
Expert Ratings for ProQR Therapeutics
Within the last quarter, ProQR Therapeutics (NASDAQ:PRQR) has observed the following analyst ratings: 
Via Benzinga
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR to Present at Upcoming Scientific and Industry Conferences
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
Dow Dips 600 Points; AMC Entertainment Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 600 points on Thursday. 
Via Benzinga
SKLZ Stock Alert: Will Skillz Shares Get Delisted?
Skillz (SKLZ) stock is worth checking on today as the company received a delisting notice from the New York Stock Exchange. 
Via InvestorPlace
Why Are Chinese EV Stocks NIO, XPEV, LI on Watch Today?
Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading on Thursday! 
Via InvestorPlace
Why Is ProQR (PRQR) Stock Up 83% Today?
ProQR (PRQR) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (LLY). 
Via InvestorPlace
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday. 
Via Benzinga
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. 
Via Benzinga
ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday! 
Via InvestorPlace
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
From ProQR Therapeutics N.V.
Via GlobeNewswire
Lilly and ProQR to Expand RNA Editing Collaboration
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology 
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Third Quarter 2022 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.